SER Serina Therapeutics, Inc.: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The share price retrospective for Serina Therapeutics, Inc. (SER) demonstrates a value of 0.00, driven by the monetization of exclusive CNS drug delivery technologies through royalties and licensing fees. Stability in these metrics is supported by streamlined polymer raw material supply chains and a network of external laboratories. The business's success is solidified by a distinguished scientific leadership team, which has ensured patent transparency and the trust of global investors.
Serina Therapeutics Inc (SER) - פילוחי מדדים ודוחות פיננסיים

The development of innovative polymer drug delivery systems creates long-term patent capitalization potential for Serina Therapeutics, Inc. (SER). By analyzing the EV/EBITDA multiple trend, an investor assesses the enterprise value relative to operating profit before depreciation and amortization. This metric determines asset management efficiency and allows for the timely identification of either company undervaluation or a critical increase in debt load amid drug development.